News Conference News HRS 2025 GLP-1 Drugs May Have Role in Secondary Prevention of AF Todd Neale April 28, 2025
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Daily News Evolocumab ‘Abjectly Fails’ Another Financial Stress Test Michael O'Riordan October 19, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
Presentation TCT 2014 Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate? Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt September 14, 2014
Presentation TCT 2014 Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry September 14, 2014